Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Giving Employees the Dream of Creating Major Firm: Mr Mascarenhas of Eli Lilly Japan
March 18, 2002
-
ARCHIVE Reform Must Be Carried Out at Any Cost: Health Minister
March 18, 2002
-
COLUMN Maurer's Healthcare Insight (26)
March 18, 2002
-
ARCHIVE Healthcare Reform Bills Approved by Government
March 18, 2002
-
ARCHIVE WORLD NEWS IN BRIEF
March 18, 2002
-
ARCHIVE BUSINESS NEWS IN BRIEF
March 18, 2002
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
March 18, 2002
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 11, 2002
-
ARCHIVE BUSINESS NEWS IN BRIEF
March 11, 2002
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
March 11, 2002
-
ARCHIVE 7 Drugs Approved, Including Sivelestat
March 11, 2002
-
ARCHIVE WORLD NEWS IN BRIEF
March 11, 2002
-
ARCHIVE Committee to Propose Basic Policy for Science and Technology
March 11, 2002
-
ARCHIVE BULLETIN
March 11, 2002
-
ARCHIVE IFN Prices to Be Cut by 25%
March 11, 2002
-
ARCHIVE Maruishi: Sales, Profits Up due to Increases in Exports
March 11, 2002
-
ARCHIVE WEBSIITE NEWS
March 11, 2002
-
ARCHIVE NCC Forecasts Survival Rates for Cancer Will Double by 2015
March 11, 2002
-
ARCHIVE Gov't to Formulate Basic Policy for New Healthcare System for Elderly in FY2002
March 11, 2002
-
ARCHIVE Novartis Foundation Provides Support for 53 Researchers
March 11, 2002
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…